The Biden administration recently announced efforts to strengthen the pharmaceutical supply chain, mitigate shortages of essential medicines, and expand domestic manufacturing. The new efforts are part of an overall package of initiatives to boost U.S. supply chains that the White Houe announced on Nov. 27. Securing the country’s supply of medicines and lowering prices have…
Court rejects Johnson & Johnson bankruptcy gambit over talc suits
A U.S. bankruptcy judge in New Jersey has dismissed a Johnson & Johnson-created company’s bankruptcy filing to resolve talc-related lawsuits. Judge Michael Kaplan’s ruling on July 28 was similar to a U.S. Court of Appeals for the Third Circuit ruling months ago, which failed to find immediate financial distress over the lawsuits. As recounted in…
3M to invest nearly $150M to boost biopharma filtration tech capabilities
3M (NYSE: MMM) today announced today that it will invest $146 million dollars to expand its capabilities to further support the fast-growing biotech manufacturing sector. The investment will include facility and equipment improvements and 60 new full-time positions in 3M manufacturing facilities in Europe. 3M said the new investment will accelerate its development and delivery of vital…
Getinge to acquire High Purity New England for up to $290M
Getinge announces today that it will purchase High Purity New England, a Smithfield, Rhode Island–based provider of custom single-use products for bioprocessing applications. The Sweden-based life sciences giant will pay SEK 1.3 billion ($120 million)for all of privately-held High Purity New England’s outstanding shares at closing. In addition, there could be a maximum earn out…
Baxter to divest its BioPharma Solutions business for $4.25B
Baxter continues to streamline, announcing today that it will sell its pharma and biotech contract manufacturing business. The Deerfield, Illinois-based medtech company — maker of diagnostic, critical care, kidney care, nutrition, hospital and surgical products and services — will sell its BioPharma Solutions (BPS) business to private equity firms Advent International and Warburg Pincus. Baxter…
SMC’s European division gets new VP and GM
Medical device and pharmaceutical contract manufacturer SMC announced today that it has appointed Uri Baruch as the new VP and GM of its European division, which includes Oval Medical Technologies and Cambridge Pharma. The appointment is effective immediately. Cambridge, U.K.–based SMC says Baruch has a wealth of experience and a proven track record of success…
Moderna earnings miss in Q4 as COVID shot demand declines
Moderna (NASDAQ:MRNA) today reported fourth-quarter results that beat the Wall Street consensus on revenue but missed on earnings. Demand for the company’s COVID-19 vaccines is down, and there is surplus production capacity. Investors reacted by sending MRNA shares down more than 1% to $156.51 apiece in morning trading. Q4 2022 Q4 2021 Change Revenue $5.1…
Qosina appoints former EssilorLuxottica exec as its EVP
Qosina announced today that it’s appointed Lee Pochter as its executive vice president. Pochter has more than 20 years of expertise in product strategy, business development, sales, marketing and supply chain management. Most recently, he was VP of the Alternative Lens Group at EssilorLuxottica. “I look forward to the guidance Lee will bring to our…
Tablet press maker Korsch acquires Medelpharm to boost R&D offerings
Korsch AG recently announced that has acquired Medelpharm and its compaction simulator technology. The financial terms of the deal were not disclosed. Korsch said Medelpharm’s compaction simulator technology adds early-stage material characterization and scale-up capability to its R&D product portfolio. The companies have 135-plus years of experience with small-scale, fully instrumented tablet compression equipment. The Korsch…
Johnson & Johnson reports mixed Q4 results amid shaky economy
Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…